Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Neoadjuvant treatment before radical prostatectomy has been proven to provide benefits on
peri-operation results, especially on reduction of tumor volume and minimization of
biochemical recurrence. This study will evaluate the efficacy and safety of abiraterone
acetate Plus androgen deprivation therapy（ADT）in high-risk localized prostate cancer with
intraductal carcinoma of the prostate（IDC-P）.